PMH20 COST OF TREATMENT OF HYPERKINETIC DISORDER IN GERMANY  by Wehmeier, PM & Rothenberger, A
A70 Abstracts
PMH19
ANTIPSYCHOTIC NON-ADHERENCE AND COSTS OF SHORT-
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Non-adherence with antipsychotic medications has been impli-
cated as a proximal cause of hospital admission in the commu-
nity treatment of schizophrenia. OBJECTIVE: To estimate the
proportions of short-term inpatient admissions and hospital days
for schizophrenia in the United States that are attributable to
non-adherence with antipsychotic medications and to calculate
the corresponding total health care costs of this care.
METHODS: A series of multivariate regressions were performed
with statewide 2001–2004 California Medicaid (Medi-Cal) data
to estimate the fraction of hospital admissions and hospital days
for schizophrenia attributable to non-adherence with antipsy-
chotic medications. The 1997 Client/Patient Sample Survey was
then used to estimate the national number and length of short-
term inpatient admissions for schizophrenia. The 2002 Survey of
Mental Health Organizations was used to produce national daily
cost estimates of inpatient psychiatric care. The fraction of inpa-
tient short-term admissions attributable to non-adherence was
then applied to national estimates of the number and costs of
inpatient treatment episodes. RESULTS: Each year in the United
States, there are approximately 216,000 short-term inpatient
admissions for the treatment of schizophrenia. These admissions
include a total of approximately 2.0 million hospital days at a
total cost of approximately 1.8 billion dollars. Eliminating 
non-adherence with antipsychotic medications would lower the
number of short-term admissions by approximately 34,300
(15.6%), reduce by approximately 236,000 the number of inpa-
tient treatment days (11.7%), and save approximately 213
million dollars (11.7%) in inpatient care costs. CONLCU-
SIONS: Non-adherence with antipsychotic medications accounts
for a considerable proportion of inpatient treatment costs for
schizophrenia. Improving adherence with antipsychotic medica-
tions would likely lead to savings by reducing the frequency and
duration of inpatient treatment.
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OBJECTIVES: To determine the cost of treatment (CoT) associ-
ated with Hyperkinetic Disorder (HD) in Germany by age and
sex and compare it to the CoT of other childhood disorders.
METHODS: Data on the CoT of various childhood disorders
(including HD, epilepsy and asthma) were provided by the
German Federal Statistical Ofﬁce for the year 2002. The data
had been gathered by the Federal Ofﬁce from health insurance
providers. The data were broken down by diagnosis, age, sex,
and the type of resource consumed (inpatient treatment, outpa-
tient treatment, medication). The CoT of HD was then compared
to the CoT of epilepsy and asthma. RESULTS: Total treatment
costs of HD were €142 million. The highest costs (€128.8
million) were in the age group 0–15 years, where HD is most
prevalent, with 0.93% of insured girls and 3.35% of insured
boys affected. Costs also reﬂect this gender difference in preva-
lence, with €104.6 million incurred by boys and €24.2 million
incurred by girls in this age group. Treatment costs can be pri-
marily attributed to inpatient treatment (41.6%), outpatient
treatment (38.9%) and medication (5.7%). The treatment cost
of HD represents 2.2% of the total CoT in the age group 0–15
years, estimated to be €5,735 million. In this age group, other
disorders such as epilepsy (or asthma) incur treatment costs of
€199 million (€245 million). For epilepsy (or asthma), inpatient
treatment accounts for 56.1% (18.6%), outpatient treatment for
11.1% (11.1%) and medication for 26.9% (59.0%) of CoT.
CONCLUSIONS: In Germany in 2002, the CoT of HD was
€128.8 million in the age group 0–15 years. The cost of HD was
lower than the cost of other common childhood diseases and 
represents only 2.2% of the total CoT in the age group 0–15
years. Whilst inpatient treatment for HD incurs 41.6% of CoT,
medication incurs 5.7%.
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OBJECTIVE: To compare the health care utilization and costs
between patients with a diagnosis of bipolar I disorder with 
psychotic symptoms (BPP) to patients with bipolar I disorder
without psychotic symptoms (BPO). METHODS: We conducted
a retrospective, independent group analysis using pharmacy and
medical claims from a large national managed care database.
Patients in each cohort were identiﬁed based on their ﬁrst claim
for a bipolar diagnosis during the 2003 calendar year. T-tests and
chi-square tests were used to compare variables between the two
groups. RESULTS: Of the 8221 patients who met study criteria,
7.9% of the BPP group (n = 5108) had at least one mental health-
related hospitalization, compared to 4.0% of the BPO group 
(n = 3113, p < 0.0001). Mean mental-health related hospital
costs per patient in the BPP group were $625 (SD $3326) com-
pared to $283 (SD $2223) in the BPO group (p < 0.0001).
Overall mean medication costs were $2638 (SD $3765) in the
BPP group compared to $2397 (SD$3482, p = 0.003), while
mean costs for outpatient visits (other than physician visits) were
not signiﬁcantly different (p = 0.078). Overall mean health care
costs were $10,263 (SD $19,962) in the BPP group compared to
$8,649 (SD $15,132) in the BPO group (p < 0.0001). CON-
CLUSIONS: Patients with bipolar I disorder with psychotic
symptoms had higher health care utilization and costs compared
to patients without psychotic symptoms. Research on interven-
tions targeting bipolar patients with psychotic symptoms may be
warranted.
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OBJECTIVES: State Medicaid programs are scrutinizing atypi-
cal antipsychotic prescribing given relatively high costs and 
use with other psychotropic medications. This study assessed
healthcare costs associated with antipsychotic polypharmacy in
ﬁve state Medicaid programs over six years. METHODS:
A retrospective cohort study using Medicaid claims data from
California, Oregon, Tennessee, Utah, and Wyoming evaluated
64,411 patients who ﬁlled an antipsychotic prescription
(1998–2003) and who were eligible 180 days prior to 365 days
after the index claim. Analysis was stratiﬁed by antipsychotic
regimen: polypharmacy (multiple antipsychotic initiation or 
